These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 9120763)
1. A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol). Lundberg BB J Pharm Pharmacol; 1997 Jan; 49(1):16-21. PubMed ID: 9120763 [TBL] [Abstract][Full Text] [Related]
2. A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration. Lundberg BB; Risovic V; Ramaswamy M; Wasan KM J Control Release; 2003 Jan; 86(1):93-100. PubMed ID: 12490375 [TBL] [Abstract][Full Text] [Related]
3. Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. Crosasso P; Ceruti M; Brusa P; Arpicco S; Dosio F; Cattel L J Control Release; 2000 Jan; 63(1-2):19-30. PubMed ID: 10640577 [TBL] [Abstract][Full Text] [Related]
4. Cremophor-free intravenous microemulsions for paclitaxel I: formulation, cytotoxicity and hemolysis. Nornoo AO; Osborne DW; Chow DS Int J Pharm; 2008 Feb; 349(1-2):108-16. PubMed ID: 17869459 [TBL] [Abstract][Full Text] [Related]
5. Design and evaluation of an emulsion vehicle for paclitaxel. I. Physicochemical properties and plasma stability. Han J; Davis SS; Papandreou C; Melia CD; Washington C Pharm Res; 2004 Sep; 21(9):1573-80. PubMed ID: 15497682 [TBL] [Abstract][Full Text] [Related]
6. Preparation and characterization of polymeric pH-sensitive STEALTH® nanoparticles for tumor delivery of a lipophilic prodrug of paclitaxel. Lundberg BB Int J Pharm; 2011 Apr; 408(1-2):208-12. PubMed ID: 21296135 [TBL] [Abstract][Full Text] [Related]
7. Formulation development and antitumor activity of a filter-sterilizable emulsion of paclitaxel. Constantinides PP; Lambert KJ; Tustian AK; Schneider B; Lalji S; Ma W; Wentzel B; Kessler D; Worah D; Quay SC Pharm Res; 2000 Feb; 17(2):175-82. PubMed ID: 10751032 [TBL] [Abstract][Full Text] [Related]
8. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing water-soluble prodrugs of paclitaxel. Ceruti M; Crosasso P; Brusa P; Arpicco S; Dosio F; Cattel L J Control Release; 2000 Jan; 63(1-2):141-53. PubMed ID: 10640588 [TBL] [Abstract][Full Text] [Related]
9. Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder cancer therapy. Mugabe C; Hadaschik BA; Kainthan RK; Brooks DE; So AI; Gleave ME; Burt HM BJU Int; 2009 Apr; 103(7):978-86. PubMed ID: 19007363 [TBL] [Abstract][Full Text] [Related]
10. A mixed micellar formulation suitable for the parenteral administration of taxol. Alkan-Onyuksel H; Ramakrishnan S; Chai HB; Pezzuto JM Pharm Res; 1994 Feb; 11(2):206-12. PubMed ID: 7909371 [TBL] [Abstract][Full Text] [Related]
11. Thermosensitive and biodegradable polymeric micelles for paclitaxel delivery. Soga O; van Nostrum CF; Fens M; Rijcken CJ; Schiffelers RM; Storm G; Hennink WE J Control Release; 2005 Mar; 103(2):341-53. PubMed ID: 15763618 [TBL] [Abstract][Full Text] [Related]
12. Cremophor-free intravenous microemulsions for paclitaxel II. Stability, in vitro release and pharmacokinetics. Nornoo AO; Chow DS Int J Pharm; 2008 Feb; 349(1-2):117-23. PubMed ID: 17869458 [TBL] [Abstract][Full Text] [Related]
13. An investigation of the antitumour activity and biodistribution of polymeric micellar paclitaxel. Zhang X; Burt HM; Von Hoff D; Dexter D; Mangold G; Degen D; Oktaba AM; Hunter WL Cancer Chemother Pharmacol; 1997; 40(1):81-6. PubMed ID: 9137535 [TBL] [Abstract][Full Text] [Related]
14. Improving anti-tumor activity with polymeric micelles entrapping paclitaxel in pulmonary carcinoma. Gong C; Xie Y; Wu Q; Wang Y; Deng S; Xiong D; Liu L; Xiang M; Qian Z; Wei Y Nanoscale; 2012 Sep; 4(19):6004-17. PubMed ID: 22910790 [TBL] [Abstract][Full Text] [Related]
15. Stability of parenteral nanoemulsions loaded with paclitaxel: the influence of lipid phase composition, drug concentration and storage temperature. Kadam AN; Najlah M; Wan KW; Ahmed W; Crean SJ; Phoenix DA; Taylor KM; Elhissi AM Pharm Dev Technol; 2014 Dec; 19(8):999-1004. PubMed ID: 24093888 [TBL] [Abstract][Full Text] [Related]
17. The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients. Malingré MM; Schellens JH; Van Tellingen O; Ouwehand M; Bardelmeijer HA; Rosing H; Koopman FJ; Schot ME; Ten Bokkel Huinink WW; Beijnen JH Br J Cancer; 2001 Nov; 85(10):1472-7. PubMed ID: 11720431 [TBL] [Abstract][Full Text] [Related]
18. Liposome formulation of paclitaxel with enhanced solubility and stability. Yang T; Cui FD; Choi MK; Lin H; Chung SJ; Shim CK; Kim DD Drug Deliv; 2007 Jul; 14(5):301-8. PubMed ID: 17613018 [TBL] [Abstract][Full Text] [Related]
19. PEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy. Yoshizawa Y; Kono Y; Ogawara K; Kimura T; Higaki K Int J Pharm; 2011 Jun; 412(1-2):132-41. PubMed ID: 21507344 [TBL] [Abstract][Full Text] [Related]
20. [Comparative study on pharmacokinetics and tissue distribution of a novel microemulsion based on the paclitaxel/L-OH lipid complex and paclitaxel injection in cremophor]. Ma YL; Ye J; Zhang PX; Xia XJ; Liu YL Yao Xue Xue Bao; 2013 Nov; 48(11):1698-704. PubMed ID: 24475708 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]